The Effect of Interferon Beta and Natalizumab on miR-20b Expression in Patients with Relapsing-Remitting Multiple Sclerosis is Potentially Mediated by Modulation of the Jak-STAT Signaling Pathway: A Case-control Study
CONCLUSION: Our findings suggest that the positive effects of IFN-β and NTZ in the RRMS patients could be potentially mediated by returning miR-20b expression to baseline.PMID:38761094 | DOI:10.22034/iji.2024.100500.2694 (Source: Iranian Journal of Immunology)
Source: Iranian Journal of Immunology - May 18, 2024 Category: Allergy & Immunology Authors: Aysan Jafari Harandi Alireza Mirzaee Sedigh Mitra Ataei Sepideh Bayrami Emran Esmaeilzadeh Mohammad Hossein Sanati Source Type: research

Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy
Conclusion Continuing natalizumab during pregnancy after gw 30 decreases the relapse risk postpartum going along with a higher risk for HA in the newborns. These results add relevant knowledge as a basis for informed risk–benefit discussion. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - May 14, 2024 Category: Neurosurgery Authors: Thiel, S., Litvin, N., Haben, S., Gold, R., Hellwig, K. Tags: Open access Multiple sclerosis Source Type: research

Long-lasting severe anemia following treatment with natalizumab for relapsing –remitting multiple sclerosis: a case report
ConclusionSevere anemia can be caused by treatment with natalizumab. This case adds information to the few other similar reported cases, demonstrating the potential duration of the anemia, as well as detailed description of hematologic findings. The mechanism is most likely due to inhibition of α4 subunit of the α4β1-integrin, which is present on both lymphocytes and erythroid precursor cells. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - May 13, 2024 Category: General Medicine Source Type: research

Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification
Progressive multifocal leukoencephalopathy (PML) is a potentially life-threatening complication among Multiple Sclerosis (MS) patients under natalizumab treatment, with serum anti-JCV antibody titers being used for stratification risk. Given the critical role of interferon (IFN)/B-cell activating factor (BAFF) axis in humoral immune responses against viruses, we explored whether it is involved in the generation of serum anti-JCV antibodies among these patients. (Source: Journal of the Neurological Sciences)
Source: Journal of the Neurological Sciences - May 12, 2024 Category: Neurology Authors: Charalampos Skarlis, Vassilis Papadopoulos, Sylvia Raftopoulou, Clio P. Mavragani, Maria-Eleftheria Evangelopoulos Source Type: research

PB006: A Natalizumab Biosimilar
AbstractPB006 (Tyruko®) is the first biosimilar of the reference monoclonal anti- α4-integrin antibody natalizumab. It is approved for use in the same indications for which reference natalizumab is approved, as a single disease-modifying therapy in adults with highly active relapsing-remitting multiple sclerosis (RRMS). PB006 has similar physicochemical and pharmacodynamic prope rties to those of reference natalizumab, and the pharmacokinetic similarity of the agents has been demonstrated in a study in healthy subjects. PB006 demonstrated clinical efficacy similar to that of reference natalizumab in patients with RRMS, a...
Source: Clinical Drug Investigation - April 29, 2024 Category: Drugs & Pharmacology Source Type: research

Treatment Monitoring in Multiple Sclerosis — Efficacy and Safety
Magnetic resonance imaging is the most sensitive method for detecting inflammatory activity in multiple sclerosis, particularly in the brain where it reveals subclinical inflammation. Established MRI markers include contrast-enhancing lesions and active T2 lesions. Recent promising markers like slowly expanding lesions and phase rim lesions are being explored for monitoring chronic inflammation, but require further validation for clinical use. Volumetric and quantitative MRI techniques are currently limited to clinical trials and are not yet recommended for routine clinical use. Additionally, MRI is crucial for detecting c...
Source: Neuroimaging Clinics - April 29, 2024 Category: Radiology Authors: Nima Mahmoudi, Mike P. Wattjes Source Type: research

Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis
ConclusionsCertain DMTs have the potential to positively impact QoL of PwMS, and the assessment and reporting of QoL is suboptimal with a multitude of diverse instruments being used. There is an urgent need that design and reporting of clinical trials reflect the critical importance of QoL for PwMS. (Source: Journal of Neurology)
Source: Journal of Neurology - April 16, 2024 Category: Neurology Source Type: research

Real-world evidence and patient preference for subcutaneous < em > versus < /em > intravenous natalizumab in the treatment of relapsing-remitting multiple sclerosis - initial results from the observational SISTER study
CONCLUSION: Based on current data, there is a trend toward patients' preference for the natalizumab SC route over the IV route, which provides valuable insights into patients' preference for natalizumab RoA in routine care and complements available data from clinical studies with real-world data on SC natalizumab.TRIAL REGISTRATION: This observational (non-interventional) study was registered in the local German PEI register for non-interventional studies (NIS-No. 611) and in the international CTgov register (NCT05304520).PMID:38616781 | PMC:PMC11015759 | DOI:10.1177/17562864241241382 (Source: Adv Data)
Source: Adv Data - April 15, 2024 Category: Epidemiology Authors: Ralf Gold Stephan Schmidt Florian Deisenhammer Jeremias Motte Nils Richter Kirsi Taipale Hans Christian Salmen Christian Bohland Ksenija Schirduan Source Type: research

Real-world evidence and patient preference for subcutaneous < em > versus < /em > intravenous natalizumab in the treatment of relapsing-remitting multiple sclerosis - initial results from the observational SISTER study
CONCLUSION: Based on current data, there is a trend toward patients' preference for the natalizumab SC route over the IV route, which provides valuable insights into patients' preference for natalizumab RoA in routine care and complements available data from clinical studies with real-world data on SC natalizumab.TRIAL REGISTRATION: This observational (non-interventional) study was registered in the local German PEI register for non-interventional studies (NIS-No. 611) and in the international CTgov register (NCT05304520).PMID:38616781 | PMC:PMC11015759 | DOI:10.1177/17562864241241382 (Source: Adv Data)
Source: Adv Data - April 15, 2024 Category: Epidemiology Authors: Ralf Gold Stephan Schmidt Florian Deisenhammer Jeremias Motte Nils Richter Kirsi Taipale Hans Christian Salmen Christian Bohland Ksenija Schirduan Source Type: research

Long-term follow up of alemtuzumab-treated patients: a retrospective study in a Belgian tertiary care center
ConclusionATZ is a high efficacy therapy for active MS, providing long-term remission in a significant proportion of patients. Retreatment was more frequent in younger patients or patients having failed a higher number of previous DMTs. (Source: Acta Neurologica Belgica)
Source: Acta Neurologica Belgica - April 15, 2024 Category: Neurology Source Type: research

Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)
Natalizumab treatment in relapsing-remitting multiple sclerosis: can we safely personalise treatment intervals? In JNNP, Toorop and coworkers present the results of the NEXT-MS trial, a clinical trial on individualised extended interval dosing (EID) of natalizumab (NTZ) in people with relapsing-remitting multiple sclerosis (RRMS).1 NTZ was one of the first high-efficacy treatments in RRMS, and has remained popular since its introduction in the late 2000s. NTZ is typically administered at a dose of 300 mg every 4 weeks. The two pivotal phase 3 NTZ trials, AFFIRM2 and SENTINEL3 were published back-to-back in the New England ...
Source: Journal of Neurology, Neurosurgery and Psychiatry - April 12, 2024 Category: Neurosurgery Authors: Koch, M. Tags: Editorial commentaries Source Type: research

Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)
Conclusions MS disease activity is adequately controlled with personalised natalizumab EID. Interval extension to a drug trough concentration of 5 µg/mL is likely a safe target to extend natalizumab treatment intervals >6 weeks. Trial registration number NCT04225312. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - April 12, 2024 Category: Neurosurgery Authors: Toorop, A. A., van Lierop, Z. Y., Gelissen, L. M., Hoitsma, E., Zeinstra, E. M., van Rooij, L. C., van Munster, C. E., Vennegoor, A., Mostert, J. P., Wokke, B. H., Kalkers, N. F., Hoogervorst, E. L., van Eijk, J. J., Roosendaal, C. M., Kragt, J. J., Eurel Tags: Editor's choice Multiple sclerosis Source Type: research

Iraqi experts consensus on the management of relapsing remitting multiple sclerosis in adults
This study aimed to develop consensus recommendations regarding the diagnosis and management of MS in Iraq, specifically focusing on treatment-naïve patients, suboptimal responders, and women of childbearing age during preconception, pregnancy planning, and lactation. A survey was conducted to collect feedback from a panel of ten key opinion leaders (KOLs), who evaluated and discussed the statements to determine agreement levels. The mini-Delphi method was employed to establish a consensus on the management recommendations, and a meeting was held to analyze the responses and ensure that the recommendations were based on c...
Source: Current Medical Research and Opinion - April 11, 2024 Category: Research Authors: Hayder K Hassoun Anmar Oday Hatem Akram Al-Mahdawi Sarwer Jamal Al-Bajalan Ali Kadim Karim Sarmad Abdulrasool Al-Mashta Saif Mohammed Tawfeeq Majeed Salih Hamad Nawfal M Sheaheed Samer Mohammed Ridha Murad Al-Naqshbandi Hasan Aziz Al-Hamadani Source Type: research